Novo Nordisk A/S
GLP-1 compositions and uses thereof
Last updated:
Abstract:
The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.
Status:
Grant
Type:
Utility
Filling date:
28 Jan 2020
Issue date:
12 Jan 2021